Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Cancer Related Pain (Breakthrough Pain)
Clinical Trial
NCT01326689Last updated: 12/4/2025
4151.T
Kyowa Kirin Co., Ltd.
